SCHEMBL3528038

SCHEMBL3528038

COC(=O)C(C)(C)OCC#Cc1cc(Cl)ccc1NS(=O)(=O)c1ccc2nc(C)sc2c1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.46
ALDH1A1 P00352 4/20 0.46
PKM P14618 2/20 0.46
HTT P42858 5/20 0.43
GPR55 Q9Y2T6 1/20 0.43
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 7/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
CYP2C9 P11712 1/20 0.40
NOD2 Q9HC29 1/20 0.40
HPGD P15428 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527218 0.94 ALDH1A1 (0.43) LMNAALDH1A1PKMHTTGPR55
SCHEMBL3529151 0.89 AKT1 (0.49) MAPK1HPGDKDM4E
SCHEMBL3523854 0.86 ALDH1A1 (0.43) LMNAALDH1A1PKMHTTMEN1
SCHEMBL3529717 0.84 CCKBR (0.42) MEN1KMT2A
SCHEMBL3526140 0.83 TRPV1 (0.45) LMNAALDH1A1PKMHTTMAPK1
SCHEMBL3524149 0.82 LMNA (0.47) LMNAALDH1A1PKMHTTGPR55
SCHEMBL3529238 0.82 ACLY (0.41) LMNAALDH1A1HTTMEN1KMT2A
SCHEMBL3523093 0.82 HTT (0.48) LMNAALDH1A1PKMHTTGPR55
SCHEMBL3529397 0.81 LMNA (0.49) LMNAALDH1A1HTTMAPK1MEN1
SCHEMBL3525458 0.81 CCR2 (0.44) LMNAALDH1A1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP LMNA 849/4885ALDH1A1 1607/4885PKM 728/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG LMNA 1980/4885ALDH1A1 1453/4885PKM 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.